Multi-faceted strategies to combat disease by interference with the chemokine system.

[1]  M. Mack,et al.  Interference with Heparin Binding and Oligomerization Creates a Novel Anti-Inflammatory Strategy Targeting the Chemokine System , 2004, The Journal of Immunology.

[2]  M. Lederman,et al.  Prevention of Vaginal SHIV Transmission in Rhesus Macaques Through Inhibition of CCR5 , 2004, Science.

[3]  S. Orkin,et al.  A Critical Role for Eosinophils in Allergic Airways Remodeling , 2004, Science.

[4]  E. Lenkiewicz,et al.  Defining a Link with Asthma in Mice Congenitally Deficient in Eosinophils , 2004, Science.

[5]  M. Tabrizi,et al.  Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study. , 2004, Chest.

[6]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[7]  G. McFadden,et al.  VIRAL CHEMOKINE-BINDING PROTEINS INHIBIT INFLAMMATORY RESPONSES AND AORTIC ALLOGRAFT TRANSPLANT VASCULOPATHY IN RAT MODELS , 2004, Transplantation.

[8]  A. Alcamí,et al.  Inhibition of intimal hyperplasia in transgenic mice conditionally expressing the chemokine-binding protein M3. , 2004, The American journal of pathology.

[9]  Yasunori Iwata,et al.  Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. , 2004, Journal of the American Society of Nephrology : JASN.

[10]  U. V. von Andrian,et al.  Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. , 2004, Annual review of immunology.

[11]  Marlene Wolf,et al.  Chemokines: multiple levels of leukocyte migration control. , 2004, Trends in immunology.

[12]  T. Williams,et al.  Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi‐step model of ligand binding and receptor activation , 2003, European journal of immunology.

[13]  W. Metz,et al.  Unraveling the chemistry of chemokine receptor ligands. , 2003, Chemical reviews.

[14]  P. Nuttall,et al.  Effect of fast protein liquid chromatography fractionated salivary gland extracts from different ixodid tick species on interleukin-8 binding to its cell receptors. , 2003, Folia parasitologica.

[15]  Timothy N. C. Wells,et al.  Glycosaminoglycan binding and oligomerization are essential for the in vivo activity of certain chemokines , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Timothy N. C. Wells,et al.  New therapeutics that modulate chemokine networks , 2002, Nature Reviews Drug Discovery.

[17]  A. Proudfoot.  Chemokine receptors: multifaceted therapeutic targets , 2002, Nature Reviews Immunology.

[18]  J. White,et al.  Nonpeptide CXCR2 antagonist prevents neutrophil accumulation in hyperoxia-exposed newborn rats. , 2001, The Journal of pharmacology and experimental therapeutics.

[19]  R. Horuk,et al.  CCR1-specific non-peptide antagonist: efficacy in a rabbit allograft rejection model. , 2001, Immunology letters.

[20]  I. Charo,et al.  Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice , 2001, Current opinion in lipidology.

[21]  S. Narula,et al.  Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. , 2001, Molecular pharmacology.

[22]  B. Rollins,et al.  Absence of Monocyte Chemoattractant Protein 1 in Mice Leads to Decreased Local Macrophage Recruitment and Antigen-Specific T Helper Cell Type 1 Immune Response in Experimental Autoimmune Encephalomyelitis , 2001, The Journal of experimental medicine.

[23]  C. Weber,et al.  A Non-peptide Functional Antagonist of the CCR1 Chemokine Receptor Is Effective in Rat Heart Transplant Rejection* , 2001, The Journal of Biological Chemistry.

[24]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[25]  H. Weiner,et al.  Resistance to Experimental Autoimmune Encephalomyelitis in Mice Lacking the Cc Chemokine Receptor (Ccr2) , 2000, The Journal of experimental medicine.

[26]  S. Goodbourn,et al.  Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. , 2000, The Journal of general virology.

[27]  W. Kuziel,et al.  Cc Chemokine Receptor 2 Is Critical for Induction of Experimental Autoimmune Encephalomyelitis , 2000, The Journal of experimental medicine.

[28]  H. Weiner,et al.  Leukocyte recruitment during onset of experimental allergic encephalomyelitis is CCR1 dependent , 2000, European journal of immunology.

[29]  D. Fremont,et al.  Identification of a Gammaherpesvirus Selective Chemokine Binding Protein That Inhibits Chemokine Action , 2000, Journal of Virology.

[30]  S. O. Smith,et al.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  R. Horuk,et al.  Species selectivity of a small molecule antagonist for the CCR1 chemokine receptor. , 2000, European journal of pharmacology.

[32]  M. Humbert,et al.  Eosinophil chemotactic chemokines (eotaxin, eotaxin-2, RANTES, monocyte chemoattractant protein-3 (MCP-3), and MCP-4), and C-C chemokine receptor 3 expression in bronchial biopsies from atopic and nonatopic (Intrinsic) asthmatics. , 1999, Journal of immunology.

[33]  E. Israel,et al.  Eotaxin and impaired lung function in asthma. , 1999, American journal of respiratory and critical care medicine.

[34]  B. Moss,et al.  IL-18 binding and inhibition of interferon gamma induction by human poxvirus-encoded proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[35]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  B. Rollins,et al.  MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. , 1999, The Journal of clinical investigation.

[37]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[38]  R. Strieter,et al.  Acute and relapsing experimental autoimmune encephalomyelitis are regulated by differential expression of the CC chemokines macrophage inflammatory protein-1α and monocyte chemotactic protein-1 , 1998, Journal of Neuroimmunology.

[39]  D. Taub,et al.  Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor* , 1998, The Journal of Biological Chemistry.

[40]  R. Hertzberg,et al.  Identification of a Potent, Selective Non-peptide CXCR2 Antagonist That Inhibits Interleukin-8-induced Neutrophil Migration* , 1998, The Journal of Biological Chemistry.

[41]  J. Gong,et al.  An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lpr Mouse Model , 1997, The Journal of experimental medicine.

[42]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[43]  M. Congreve,et al.  Searching for Chemokine Receptor Binding Antagonists by High Throughput Screening , 1997 .

[44]  M. Montjovent,et al.  Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.

[45]  B. Cohen,et al.  Soluble and membrane‐anchored forms of the human IFN‐α/β receptor , 1995, Journal of leukocyte biology.

[46]  J. Hsuan,et al.  Eotaxin: a potent eosinophil chemoattractant cytokine detected in a guinea pig model of allergic airways inflammation , 1994, The Journal of experimental medicine.

[47]  P. Murphy,et al.  Cloning of complementary DNA encoding a functional human interleukin-8 receptor. , 1991, Science.

[48]  W I Wood,et al.  Structure and functional expression of a human interleukin-8 receptor. , 1991, Science.

[49]  M. T. Brewer,et al.  Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist , 1990, Nature.

[50]  J. Dayer,et al.  A human inhibitor of tumor necrosis factor alpha , 1988, The Journal of experimental medicine.

[51]  E. Clark,et al.  Molecules mediating adhesion of T and B cells, monocytes and granulocytes to vascular endothelial cells. , 1988, Immunology.

[52]  F. Sánchez‐Madrid,et al.  A human leukocyte differentiation antigen family with distinct alpha- subunits and a common beta-subunit: the lymphocyte function-associated antigen (LFA-1), the C3bi complement receptor (OKM1/Mac-1), and the p150,95 molecule , 1983, The Journal of experimental medicine.

[53]  Andro R. Hsu,et al.  Chemokine-receptor interactions: GPCRs, glycosaminoglycans and viral chemokine binding proteins. , 2004, Advances in protein chemistry.

[54]  Antonio Alcami,et al.  Viral mimicry of cytokines, chemokines and their receptors , 2003, Nature Reviews Immunology.

[55]  G. Fantuzzi,et al.  Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. , 1999, Immunity.